VARGATEF®: extending survival, even where you may not expect it

New ESMO Guideline 2018


VARGATEF® is indicated in combination with docetaxel for the treatment of adult patients with locally advanced, metastatic or locally recurrent non-small cell lung cancer (NSCLC) of adenocarcinoma tumour histology after first-line chemotherapy.

Indication Read More


VARGATEF® (nintanib) dose adjustment can be an important strategy to help manage adverse reactions.

Dosing Read More


The Clinical library includes videos, clinical papers and case studies which support the clinical trial data and real world experience of healthcare professionals using VARGATEF®.

AE management Read More